An observational study in Health Services Research, Quality of Life and Addiction, sponsored by University Paris 7 - Denis Diderot. Status unknown at 2 sites in France. Open to participants aged 16 Years to 67 Years. Per ClinicalTrials.gov, last updated 2020-11-04.
Sponsored by University Paris 7 - Denis Diderot · Observational
The current context of the Covid-19 health crisis leads to an over-solicitation of health systems, with hospital staff in the front line. These personnel are undergoing high levels of stress, an alteration of their life rhythm, but also of their health status and quality of life at work. In addition, night work, through the disruption of circadian rhythms, has consequences on physical and mental health. The more frequent worsening of the condition of certain patients at night increases the burden and responsibilities of night staff. Increasing the use of psychoactive substances (SPAs) can become a solution for managing stress, work rhythms, sleep disorders and their consequences. This self-medication behaviour is not without risks, neither for staff nor for patients.
The ALADDIN study is a project made up of 2 waves of questionnaires - one during and the other after the Covid "hospital" crisis - filled in by the hospital night staff of AP-HP. This project will assess the impact of the Covid-19 epidemic on the quality of work life, mental health disorders, post-traumatic stress and substance use of hospital night staff.
The main objectives of this study is to evaluate the prevalence of psychoactive substance consumption among the night shift healthcare workers of the AP-HP and to describe the participants' quality of working life.
Methods The study is prospective study using an online self-completed questionnaire. The questionnaire was elaborated on the basis of the validated scales ASSIST (Alcohol, Smoking, and Substance Involvement Screening Test), AUDIT-C (Alcohol Use Disorder Test, shortened version) and HAD (for anxiety and depression) and on qualitative interviews conducted among care staff working the night shift.
The questionnaire will be completed at t0 (baseline) and 18 months after. This study will provide data on the consumption psychoactive substances by night hospital workers adn their quality of working life. It will also allow us to compare their consumption with the general population, and to describe the risk factors influencing the consumption.
2,238 studies on the registry are indexed under Substance-Related Disorders; 409 are open to participants now.
This study's planned enrollment of 1,800 is above the median of 251 across 299 observational studies indexed under Substance-Related Disorders.
Browse Substance-Related Disorders studies →University Paris 7 - Denis Diderot is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Compared within Substance-Related Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Behavior, Addictive. The counts are of registry records indexed under each term, refreshed daily. How we classify →
As night workers are more prone to impaired health and to addictions, the study focuses on hospital night workers who represent a population particularly at risk.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Substance use prevalence
Prevalence in APHP health workers of psychoactive substance consumption during the Covid 19 outbreak
Time frame: at T0 month : baseline
Quality of working life scale
Evaluation of the quality of working life during the Covid 19 outbreak using a validated scale
Time frame: at T0 month : baseline
Intervention preference
Identify the preferences for intervention to improve the quality of life or change the addictive risk of night hospital staff at the APHP. Preferences for intervention methods and ranking of the least preferred.
Time frame: at T0 month
Psychoactive substance consumption and associated factors
Describe the risk factors associated with the consumption of psychoactive substances (PAS). Logistic or fish linear regression depending on the type of variable taken into account.
Time frame: at T0 month
Impact of substance consumption on quality of life at work
Evaluate the impact of substance use on quality of life at work Principal component analysis and classification to see if there are consumer groups for the night and / or day population. Method for taking into account missing, unused or invalid data
Time frame: at T0 month
Risk factors associated with tobacco use
Describe the risk factors associated with tobacco use among night hospital workers,
Time frame: at T0 month
Impact of sleep quality on quality of working life and perceived health
Evaluate the impact of sleep quality on the quality of working life and perceived health of night staff
Time frame: at T0 month
Impact of anxiety and depressive symptoms on sleep and QWL.
Describe the links between QWL and sleep, anxiety, depressive syndromes, and workplace upheaval.
Time frame: at T0 month
Impact of sleep and workplace upheaval on anxiety and depressives symptoms
Describe the links between anxiety/depressive syndromes and workplace disruption, sleep, and the Covid epidemic.
Time frame: at T month
Modification of quality of working life score and psychoactive substances consumption prevalences
Comparison between the baseline score and prevalences and the score and prevalences 18 months after
Time frame: T18 months
Comparison of modification of quality of life score and declared quality of life modification after 18 month
Analysis of the relation between declared change and evolution of the quality of life score
Time frame: T18 months
Started Jun 2020 (actual). Primary completion is estimated for Apr 2022, 21 months after the start.
Of 122 non-industry observational studies under Substance-Related Disorders, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 21 months is below that.
Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 18 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Paris 7 - Denis Diderot